PTCT PTC Therapeutics (PTCT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001070081
Form 144 · 9
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
221
13F, latest reported quarter
Conversions, 180 days
29
Codes C/M, not in net · $6.6M priced
What the filings say about PTCT
Insiders, 180 days
-$25.1M net sold
9 sellers · 32% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$8.9M
9 notices
PTC Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, PTC THERAPEUTICS, INC. insiders sold a net $25.1M of stock across 498 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Oct 7, 2026.
- The trade is 0.2% of the 1,291,976 shares held after it.
- 2 other insiders sold within 30 days.
- 221 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SCHMERTZLER MICHAEL sold about $126.1K of PTCT under a 10b5-1 plan on Oct 14, 2026; 2 other insiders sold within 30 days and 221 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Oct 7, 2026.
- The trade is 0.0% of the 1,291,594 shares held after it.
- 2 other insiders sold within 30 days.
- 221 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SCHMERTZLER MICHAEL sold about $23.0K of PTCT under a 10b5-1 plan on Oct 14, 2026; 2 other insiders sold within 30 days and 221 funds added in the latest 13F quarter.Context
- 125 earlier Form 4 trades (code P or S) here by this insider (125 sales), the last on Oct 6, 2026.
- The trade is 0.2% of the 105,272 shares held after it.
- 2 other insiders sold within 30 days.
- 221 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EXEC. VP AND CLO Boulding Mark Elliott sold about $12.3K of PTCT under a 10b5-1 plan on Oct 9, 2026; 2 other insiders sold within 30 days and 221 funds added in the latest 13F quarter.Context
- 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Sep 17, 2026.
- The trade is 0.2% of the 1,294,147 shares held after it.
- 2 other insiders sold within 30 days.
- 221 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SCHMERTZLER MICHAEL sold about $155.1K of PTCT under a 10b5-1 plan on Oct 7, 2026; 2 other insiders sold within 30 days and 221 funds added in the latest 13F quarter.Context
- 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Sep 17, 2026.
- The trade is 0.0% of the 1,294,094 shares held after it.
- 2 other insiders sold within 30 days.
- 221 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SCHMERTZLER MICHAEL sold about $3.4K of PTCT under a 10b5-1 plan on Oct 7, 2026; 2 other insiders sold within 30 days and 221 funds added in the latest 13F quarter.498 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$25.1M over 180 days
-$8.5M over 90 days
below 89% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
221 funds bought in last quarter
more than 92% of Pharma & Biotech
Revenue
+114.5% year over year
more than 85% of Pharma & Biotech
Margin
39.4% net margin
more than 94% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.4% of the float short (float per yahoo 2026-10-26) · 6.1 days to cover · settled 2026-09-30
more than 74% of Pharma & Biotech
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Oct 16Director SCHMERTZLER MICHAEL sold $307.5K under a 10b5-1 plan (4 trades, Oct 7 to Oct 14)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 13EXEC. VP AND CLO Boulding Mark Elliott sold $145.1K under a 10b5-1 plan (3 trades, Oct 5 to Oct 9)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 7Affiliate of Director Section Six Partners, L.P. filed to sell $643.5K by Oct 7 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 2Director STEELE GLENN JR MD PHD sold $781.9K under a 10b5-1 plan (Sep 30)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 30Director STEELE GLENN JR MD PHD filed to sell $781.9K by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch PTCT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-8.6%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PTCT: institutional holders (13F)
13F holdings, latest reported quarter
13,964,554 sh
$1.1B
7,746,415 sh
$631.9M
7,236,402 sh
$590.2M
4,928,111 sh
$402.0M
4,598,952 sh
$375.1M
Congress trades in PTCT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PTCT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Boulding Mark Elliott
Filed 2026-10-09
$12.3K
Section Six Partners, L.P.
Filed 2026-10-07
$643.5K
Boulding Mark Elliott
Filed 2026-10-06
$27.9K
Boulding Mark Elliott
Filed 2026-10-05
$104.9K
STEELE GLENN JR MD PHD
Filed 2026-09-30
$781.9K
PTCT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P SmallCap Health Care ETF
$4.2M position · as of 2026-05-31
3.2%
WPG Partners Select Small Cap Value Fund
$6.4M position · as of 2026-05-31
2.7%
Invesco Biotechnology & Genome ETF
$7.0M position · as of 2026-07-31
2.5%
Guardian Small Cap Value Diversified VIP Fund
$3.7M position · as of 2026-06-30
2.3%
WPG Partners Small Cap Value Diversified Fund
$796.3K position · as of 2026-05-31
2.2%
Franklin Biotechnology Discovery Fund
$19.0M position · as of 2026-07-31
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
22 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
6
Phase 2
2 active
8
Phase 3
3 active
2
Not applicable
0 active
5
Multi-phase
0 active
What changed recently
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinop
2026-10-09 · Completed → Terminated · Sponsor decision
Phase 3
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
2026-09-10 · Completion moved 2026-06-30 → 2026-07-21
Phase 3
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
2026-09-10 · Active Not Recruiting → Completed
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Ptc Therapeutics, Inc. Political Action Committee (Ptc-Pac)
Cycle 2026 · $123K spent
$117.0K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Matthew Klein
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$7.4M
$14.7M
$2.3M
-26%
-9%
2022
$7.2M
$5.4M
$3.4M
-38%
-12%
2021
$11.0M
-$4.9M
$4.3M
-35%
-1%
2020
$10.6M
$12.6M
$4.0M
+27%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $25.1M sold by insiders over 180 days, 221 funds added last quarter, $8.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
PTCT financials
Revenue growth
+114.5%
XBRL, annual
Net margin
39.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PTCT
| FY Dec 2025 | $1.7B |
| FY Dec 2024 | $806.8M |
| FY Dec 2023 | $937.8M |
| FY Dec 2022 | $698.8M |
| FY Dec 2021 | $538.6M |
| Jun 2026 | $360.5M |
| Mar 2026 | $272.6M |
| Dec 2025 | $164.7M |
| Sep 2025 | $211.0M |
| Jun 2025 | $178.9M |
| Mar 2025 | $1.2B |
| Dec 2024 | $213.2M |
| Sep 2024 | $196.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-3.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PTCT
| FY Dec 2025 | +39.5% |
| FY Dec 2024 | -45.0% |
| FY Dec 2023 | -66.8% |
| FY Dec 2022 | -80.0% |
| FY Dec 2021 | -97.3% |
| Jun 2026 | +23.2% |
| Mar 2026 | -1.0% |
| Dec 2025 | -81.7% |
| Sep 2025 | +7.5% |
| Jun 2025 | -36.3% |
| Mar 2025 | +73.7% |
| Dec 2024 | -30.9% |
| Sep 2024 | -54.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$39.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PTCT
| FY Dec 2025 | $702.3M |
| FY Dec 2024 | -$114.2M |
| FY Dec 2023 | -$186.9M |
| FY Dec 2022 | -$388.7M |
| FY Dec 2021 | -$279.5M |
| Jun 2026 | $126.9M |
| Mar 2026 | -$60.2M |
| Dec 2025 | -$36.6M |
| Sep 2025 | -$69.8M |
| Jun 2025 | -$59.6M |
| Mar 2025 | $868.4M |
| Dec 2024 | -$33.8M |
| Sep 2024 | -$77.5M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity PTCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 300.02x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.05x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt PTCT
| FY Dec 2025 | 1.24x |
| FY Dec 2024 | -0.25x |
| FY Dec 2023 | -0.36x |
| FY Dec 2022 | -0.49x |
| FY Dec 2021 | -0.58x |
| Jun 2026 | -0.05x |
| Mar 2026 | -0.38x |
| Dec 2025 | 1.24x |
| Sep 2025 | 1.25x |
| Jun 2025 | 1.62x |
| Mar 2025 | 1.59x |
| Dec 2024 | -0.25x |
| Sep 2024 | -0.41x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity PTCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -216.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-1.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PTCT
| FY Dec 2025 | +29.7% |
| FY Dec 2024 | -20.2% |
| FY Dec 2023 | -34.8% |
| FY Dec 2022 | -30.7% |
| FY Dec 2021 | -25.3% |
| Jun 2026 | -1.3% |
| Mar 2026 | -6.7% |
| Dec 2025 | +29.7% |
| Sep 2025 | +33.5% |
| Jun 2025 | +27.7% |
| Mar 2025 | +26.8% |
| Dec 2024 | -20.2% |
| Sep 2024 | -29.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital PTCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+5.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PTCT
| FY Dec 2025 | +56.8% |
| FY Dec 2024 | -25.0% |
| FY Dec 2023 | -33.9% |
| FY Dec 2022 | -32.8% |
| FY Dec 2021 | -22.3% |
| Jun 2026 | +5.6% |
| Mar 2026 | -2.9% |
| Dec 2025 | +56.8% |
| Sep 2025 | +51.6% |
| Jun 2025 | +43.4% |
| Mar 2025 | +43.5% |
| Dec 2024 | -25.0% |
| Sep 2024 | -13.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PTCT
| FY Dec 2025 | 9.81x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 9.81x |
| Sep 2025 | 7.17x |
| Jun 2025 | 7.01x |
| Mar 2025 | 7.83x |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$4.6B
market value at close 2026-10-26 on 2026-07-29 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value PTCT
| FY Dec 2025 | $5.7B |
| FY Dec 2024 | $3.1B |
| FY Dec 2023 | $1.9B |
| FY Dec 2022 | $3.2B |
| FY Dec 2021 | $3.1B |
| Jun 2026 | $217.7M |
| Mar 2026 | $5.4B |
| Dec 2025 | $5.7B |
| Sep 2025 | $4.8B |
| Jun 2025 | $3.3B |
| Mar 2025 | $3.0B |
| Dec 2024 | $3.1B |
| Sep 2024 | $2.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-0.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield PTCT
| FY Dec 2025 | +11.5% |
| FY Dec 2024 | -3.3% |
| FY Dec 2023 | -9.0% |
| FY Dec 2022 | -14.2% |
| FY Dec 2021 | -9.9% |
| Jun 2026 | -5.9% |
| Mar 2026 | -4.0% |
| Dec 2025 | +11.5% |
| Sep 2025 | +14.5% |
| Jun 2025 | +18.0% |
| Mar 2025 | +17.2% |
| Dec 2024 | -3.3% |
| Sep 2024 | -6.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PTCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.7B | $806.8M | $937.8M | $698.8M |
| Operating income | $866.9M | -$302.6M | -$439.5M | -$447.4M |
| Net income | $683.0M | -$363.3M | -$626.6M | -$559.0M |
| EPS (diluted) | 7.78 | -4.73 | -8.37 | -7.79 |
| Operating cash flow | $711.2M | -$107.7M | -$158.4M | -$356.7M |
| Cash | $984.6M | $779.7M | $594.0M | $279.8M |
| Long-term debt | n/a | $285.4M | $284.2M | $571.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
PTCT Stock Sonar score 6/7 axes
Find similar shapesComparePTCT ranks highest on profitability (84th percentile) and institutional and government (84th), and lowest on insider conviction (5th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PTCT filings, in plain words
Are PTC Therapeutics insiders buying or selling PTCT?
In the 180 days to 2026-10-28, PTC Therapeutics insiders were net sellers, a net $25.1M across purchases and sales reported on Form 4, by 9 sellers.
Are there planned insider sales of PTCT?
Yes. 9 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $8.9M of stock; the latest, by Boulding Mark Elliott, was filed 2026-10-09.
Read the full summary
In the 180 days to 2026-10-28, PTC Therapeutics insiders were net sellers of PTCT, a net $25.1M across purchases and sales reported on Form 4 by 9 sellers. 32% of the 75 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 9 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $8.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
